Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single-Dose Open-label Randomized Crossover, in Two Periods and in Two Sequences, Single-Center Comparative Bioequivalence Study of Two Formulations Lamotrigine, 100 mg Tablets (Pharmtechnology LLC, Republic of Belarus), and Lamictal®, 100 mg Tablets (GlaxoSmithKline Trading Closed Joint-Stock Company (CJSC), Russia), in Healthy Volunteers Under Fasting Conditions

NCT03898011 is registered in ClinicalTrials.gov with Pharmtechnology LLC as lead sponsor.

NCT NCT03898011
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03898011 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single-Dose Open-label Randomized Crossover, in Two Periods and in Two Sequences, Single-Center Comparative Bioequivalence Study of Two Formulations Lamotrigine, 100 mg Tablets (Pharmtechnology LLC, Republic of Belarus), and Lamictal®, 100 mg Tablets (GlaxoSmithKline Trading Closed Joint-Stock Company (CJSC), Russia), in Healthy Volunteers Under Fasting Conditions
Lead sponsor
Pharmtechnology LLC
Phase
Phase 1
Overall status
Completed
Start date
March 23, 2019
Completion date
May 4, 2019
Enrollment
28 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy adults